Loading
Trastuzumab deruxtecan / Breast Cancer · Phase 4 Trial
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a clinical trial registry record for a Phase 4 prospective, multi-centre, single-arm study of trastuzumab deruxtecan safety in Indian patients with HER2-positive breast cancer. Recruitment is complete (100 enrolled), but no results are posted in this registry record; the study remains ongoing or recently completed.
Phase 4, Interventional, Single Group, Open label, Treatment purpose. BREAST CANCER; age from 18 Years. Intervention: Single Arm. n = 100. 7 sites: India.
This is a clinical trial registry record for a Phase 4 prospective, multi-centre, single-arm study of trastuzumab deruxtecan safety in Indian patients with HER2-positive breast cancer. Recruitment is complete (100 enrolled), but no results are posted in this registry record; the study remains ongoing or recently completed.
This is a registry record only; no efficacy or safety results are reported. No effect sizes, adverse event rates, or comparative safety data are available in this record.
Results from this study, when reported, will inform the safety profile of trastuzumab deruxtecan in an Indian cohort. Current registry record provides no outcome data; clinicians should await published results.
Registry record for an active Phase 4 safety study with no results posted; enrollment is complete but outcome data are not yet reported.
As stated by the source record.
Quoted from the source exactly as published.
Results from this study, when reported, will inform the safety profile of trastuzumab deruxtecan in an Indian cohort. Current registry record provides no outcome data; clinicians should await published results.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06429761). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 100 participants (ACTUAL). Conditions: BREAST CANCER. Interventions: DRUG: Trastuzumab deruxtecan. Primary outcome measures: To assess the safety of trastuzumab deruxtecan in adult Indian patients , 6 Months. Brief summary: A PROSPECTIVE, MULTI-CENTER, PHASE 4, SINGLE ARM STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.